Technology evaluation: T-cell activator, Xenova.
TA-HPV (therapeutic antigen-human papilloma virus) is a vaccine being developed by Xenova (formerly Cantab) for the potential treatment of cervical cancer. The antigen is intended to activate HPV-specific cytotoxic T-cells to attack tumor cells containing the viral antigen. Over 70% of patients with cervical cancer have tumor cells containing papillomavirus DNA [173070]. TA-HPV has reached phase IIa trials in 60 patients with high-grade anogenital intraepithelial neoplasia, including VIN3 (grade 3 vulvar intraepithelial neoplasia), to evaluate clinical efficacy [381386], [427159], [429895]. In addition, a phase II 'prime-boost' study of TA-HPV in combination with TA-CIN has been initiated at three centers across the UK [427159].
Knutson
K L
KL
University of Washington, Seattle 98195, USA. kknutson@u.washington.edu
D000818:Animals; D002986:Clinical Trials as Topic; D000075202:Contraindications; D005260:Female; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D030361:Papillomavirus Infections / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*; D014412:Tumor Virus Infections / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000628:therapy*; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*
D014765:Viral Vaccines